
Opinion|Videos|January 3, 2025
Exploring Updates on AMPLIFY at ASH 2024
Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from the AMPLIFY trial.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
3
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
4
Understanding the Sequencing Decisions in mCRPC After Progression on ADT/ARPI
5






























